Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 149Fluorouracil 136Gemcitabine 117Bevacizumab 115Leucovorin 106Specimen Handling 105Capecitabine 95pembrolizumab 89Magnetic Resonance Spectroscopy 83Cisplatin 79Nivolumab 77Irinotecan 71durvalumab 63Cetuximab 62Paclitaxel 60Biopsy 60130-nm albumin-bound paclitaxel 60atezolizumab 44Radiotherapy 44Taxes 36Carboplatin 36Albumin-Bound Paclitaxel 36Folfox protocol 35Drug Therapy 31Cyclophosphamide 30lenvatinib 29dehydroftorafur 28tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × Gastrointestinal × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡